Principal Investigator: Sanjay R. Jain, MD
Coordinator: Sharion L. Smith, RN, MSN
Date IRB Approved April 20, 2016
Target Enrollment #: 10-20
Lay Summary
Study Title: A Clinical Trial of Pembrolizumab (MK3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
This is a non-randomized, multi-site, open label trial of pembrolizumab (MK3475) in subjects with multiple types of advanced rare cancers to be conducted in conformance with Good Clinical Practices. The primary purpose of this trial is to assess the Objective Response Rate to treatment with pembrolizumab
This study is for the treatment of subjects with any of the following advanced (unresectable and/or metastatic) solid tumor types:
- Anal Carcinoma
- Biliary Carcinoma
- C. Neuroendocrine Tumors (well and moderately-differentiated, including Carcinoma)
- Endometrial Carcinoma
- Cervical Carcinoma
- Vulvar Carcinoma
- Small Cell Lung Carcinoma
- Mesothelioma
- Thyroid Carcinoma
- Salivary Gland Carcinom
OR
- Any other advanced solid tumor, with the exception of colorectal carcinoma (CRC).